Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Oncology and CVMD


One of the main goals of translational research for oncology is to discover biomarkers which predict clinical efficacy. With the world’s largest collection of over 1,000 well-characterized PDX models, HuPrime®, and HuBase™ (a comprehensive database of genotypic, pharmacological, and patient clinical data on HuPrime models), Crown Bioscience is enabling drug discovery organizations to perform human surrogate Phase II-like mouse clinical trials, also known as HuTrials™, to identify suitable disease indications and discover and validate predictive biomarkers for their therapies. At the recent AACR annual meeting, Crown Bioscience presented an original research poster on the parameters...

Read more

Crown Bioscience attended the 105th Annual Meeting of the American Association for Cancer Research in San Diego last month, the theme of which was Harnessing Breakthroughs – Targeting Cures. As well as presenting 8 scientific posters on recent Crown Bioscience advances and manning a booth (both of which incorporated the latest Layar technology), Crown Bioscience also reviewed the rest of the research on display at the conference.

Read more

Screening for cervical cancer is vitally important as it is one of the few cancers that can actually be prevented by picking up early cellular changes before the disease develops. Recent advances in molecular testing had resulted in the mainstay Pap screening test being combined with a test for human Papillomavirus (HPV) DNA, which causes more than 99% of all cervical cancers. However, a new approval from the FDA that allows the HPV test to become a stand-alone first-choice screening option has prompted fierce debate on which test should be the initial testing gold standard. As this debate rolls on, Crown Bioscience asks whether this is time well spent, or whether it would be better used...

Read more